Pfizer Introduced Top-Line Achievements for Lyrica Capsules Survey

Pfizer Inc. introduced top-line results for Lyrica capsules Survey A0081147 - Long Term Overall safety and Efficacy of Pregabalin in Topics along with Generalized Anxiety Disorder (GAD) - demonstrate that drug termination symptoms were really low after tapering Lyrica therapy following three months and six months in GAD affected individuals.

The European Medicines Agency (EMA) asks for this study to check out the partnership between dose and duration of treatment on termination symptoms, such as rebound anxiety, following long-term therapy along with Lyrica in GAD patients. Pfizer will carry to firmly further analyze these top-line achievements.

Lyrica is given approval for the remedy for GAD in adults within the European Union and a number of other other regions worldwide, although not in the United States.

GAD is a chronic, disabling illness characterised by extreme anxiety and worry for about six months in period. Often lasting more time than five years, GAD symptoms are both viewed as psychological symptoms such as anxious mood, heightened fears, feelings of tension, difficulty concentrating and physical symptoms namely fatigue, pain, feelings of weakness, gastrointestinal disturbance, palpitations, sleep disturbance and restlessness.